NEW YORK, May 11 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company with a focus on niche drug delivery technologies and products, will make a presentation at the Rodman & Renshaw Global Healthcare Conference. The conference will be held next week in Monte Carlo, Monaco on May 15-16, 2005. Inyx will present at 8:20 a.m. Central Europe time on Tuesday, May 16. The Inyx presentation will also be webcast live at: http://www.wsw.com/webcast/rrshq8/iyxi.ob and it will be archived for 90 days at that site as well as at Inyx's own website. Inyx will also be available for meetings with investors attending the conference. At the conference, Inyx will discuss several strategic growth initiatives that it has recently announced and related updated financial guidance. On April 3, 2006, Inyx reported it reached an agreement in principle to acquire a German pharmaceutical production business from a pan-European specialty pharmaceutical company, with which it is also entering into a strategic, 10-year collaboration agreement, whereby Inyx will become the exclusive manufacturing resource for the European company's therapeutic products. The acquisition and collaboration also includes Inyx receiving several product licenses. The purchase price was not disclosed. The acquisition, which is subject to completion of customary due diligence, execution of definitive documents and securing financing for the closing, is expected to be completed by June 30, 2006. The pending acquisition and strategic collaboration is expected to add approximately $100 million in annualized revenues, with a 35%-40% gross margin, to Inyx. About Inyx Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: http://www.inyxgroup.com/. Safe Harbor Statements about Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results. For more information, please contact: Bill Kelly, VP Investor Relations Inyx, Inc. DATASOURCE: Inyx, Inc. CONTACT: Bill Kelly, VP Investor Relations of Inyx, Inc., Web site: http://www.inyxinc.com/

Copyright